Cannasouth is committed to expanding the understanding of the therapeutic benefits of cannabinoid-based treatments and medicines. Our research will cover key areas that phyto – cannabinoids are showing positive health outcomes and efficacy within. Such as neuropathic pain, epilepsy and inflammation. The health issues and conditions that fall under these groupings are many and varied. All humans and animal species possess an Endocannabinoid System (ECS) The ECS regulates a variety of biological processes within all mammalian species. The Endocannabinoid System performs many different tasks, but overall the function of the ECS is the regulation of homoeostasis (balance).

There are two main types of Cannabinoid receptors CB1 and CB2 within cells throughout the body. These Cannabinoid receptors are most abundant in the brain and immune system respectively. Your body naturally makes its own (Endocannabinoids like anandamide and 2-AG) these share a similar chemical structure with plant-based Cannabinoids like CBD – Cannabidiol. CBD research is central to our development programmes; we are also focusing on other key Cannabinoids such as CBDA, CBDV, CBDVA, CBN CBC, and associated compounds. Our clinical research will focus on developing safe, well-characterized and specifically defined Cannabinoid and Terpene profiles that meet regulatory standards for clinical research.



Cannasouth is located at “Waikato Innovation Park” Ruakura, Hamilton and has established a Ministry of Health licensed modern well equipped research facility and laboratory to enable the further development of New Zealand based cannabinoid science research expertise.

In 2016 the University of Waikato, a collaborative research partner of the directors of Cannasouth was granted a Ministry of Health controlled drugs licence for (Tetrahydrocannabinols) (including CBD and CBDA) for extraction and fractionation for the purpose of research and analytical work.

During 2017 the directors of Cannasouth and the University of Waikato completed an AGMARDT funded Master’s thesis on HPLC prep fractionation and purification of cannabinoid compounds such as CBD and CBDA characterised via NMR and GC. This fractionation research study program was leveraged off one of New Zealand’s first Super Critical Co2 carbon dioxide cannabinoid extraction trials that was undertaken by the directors of Cannasouth in collaboration with Callaghan Innovation.

The directors of Cannasouth in collaboration with researchers at Waikato University have now successfully produced CBD, THC and CBDA THCA isolate compounds sourced from our New Zealand based plant cultivation research and breeding programme.

In early 2018 Cannasouth launched a Callahan Innovation funded 3-year PhD study focusing on Super critical Co2 carbon dioxide extraction, Short path molecular distillation and other fractionation, purification areas of research. This PhD will be conducted within our Waikato Innovation Park research laboratory and the University of Waikato research facilities. Our Innovation Park Laboratory facility is currently being equipped with the following lab equipment:

  • Super Critical Co2 fluid extraction/ analytical and preparative.
  • Analytical Preparative HPLC Chromatography.
  • Short path fractional distillation.
  • Un-denatured Ethyl Alcohol – extraction.
  • Advanced compound purification systems.
  • Associated Laboratory equipment and support systems.

This laboratory facility will enable Cannasouth to stay well positioned within this sector. Cannasouth has also partnered with a world renowned experienced internationally based cannabinoid genetics partner to further support our New Zealand based research and development programmes.


Cannasouth is currently engaged in the development of several research programmes with Universities and research institutions regarding the facilitation of cannabinoid research within New Zealand and has a number of medical cannabinoid research areas that it is actively involved with. We are committed to developing world-leading research programmes in conjunction with our academic research partners to explore, discover and develop scientifically proven therapeutic cannabinoid solutions for our patients.

  • Developing specific cannabinoid and terpenoid profiles for therapeutic drugs based on preclinical and clinical data
  • Generating relevant biopharmaceutical parameters of cannabinoid compounds
  • Establishing and maintaining a pharmacovigilance database
  • Launching partnerships with experts in relevant disease areas
  • Cannabinoid – Appetite stimulation and weight gain
  • Cannabinoid – Inhibition of neurodegeneration
  • Cannabinoid – Neuropathic pain reduction
  • Cannabinoid – Epilepsy reduction in seizure frequency